Hybrid Concepts International
Built for the Complexity of Advanced Therapies that Require Multi-Disciplinary Deep Subject Matter Expertise

Dr. Michael Mendicino, Founder and President

Cell therapies, gene therapies, regenerative medicine products and other advanced therapeutic platforms require expertise across regulatory strategy, quality, manufacturing, CMC, clinical development, preclinical development, market access and FDA interactions both flexibly and simultaneously. Most consulting organizations are not built exclusively for that reality.

Meet Hybrid Concepts International

For more than the last decade, the company has operated as a one-stop-shop consulting and advisory firm dedicated exclusively to advanced therapies and the technologies, platforms and service providers that support them, including cell therapy, gene therapy, gene editing, regenerative medicine, tissue engineering and xenotransplantation.

Unlike individual consultants, generalized life sciences advisory firms or organizations that rely heavily on junior execution teams, HCI combines more than 60 senior specialists, including numerous ex-FDA experts, across regulatory, quality/GxP, manufacturing/facility, clinical, market access, preclinical and CMC disciplines, all focused exclusively on advanced therapies. The model allows clients to access multi-disciplinary expertise through a single organization rather than assembling multiple specialized providers. While this model supports therapeutic companies of all sizes and stages, HCI also supports platform developers, service providers like CDMOs and CROs, larger generalized consulting firms needing advanced therapy SME expertise for its clients, and investors of all types (institutional, corporate, VC, PE, angel, etc.) needing diligence for licensing, build out, M&A and other related activities.

In contrast to larger consulting firms that divide resources across small molecules, classical biologics, medical devices and multiple unrelated healthcare sectors, HCI was founded with and has remained intentionally focused on advanced therapies. That specialization has become one of the company's strongest differentiators.

"We only work on advanced therapies," says Dr. Michael Mendicino, Founder and President of Hybrid Concepts International . "We don't do small molecules, classical biologics or devices unless they directly support the advanced therapy space."

Built Around Deep Subject Matter Expertise

Dr. Mendicino's background includes academic science, FDA experience and scientific and regulatory roles within biotech organizations before launching HCI a decade ago. Throughout that time, he has worked exclusively inside advanced therapies. This continuity shaped how the company was built.

Over time, Dr. Mendicino noticed a recurring problem across the consulting landscape. Many firms promoted advanced therapies capabilities, but very few were actually structured around them operationally. Some treated advanced therapies as one vertical amongst many. Others relied on senior leaders to win projects while junior teams performed much of the execution work behind the scenes.

HCI took, and still takes, a different approach.

"There are firms where experienced people sell the work, but junior people are doing most of the heavy lifting behind the scenes," Dr. Mendicino says. "Our model is built around senior expertise actually performing the work."

Today, the company operates with more than 60 senior specialists across regulatory, quality, CMC, manufacturing, preclinical development and operations, clinical development and operations, GMP and GLP Facility turn-key support, medical and technical writing (regulatory documentation and journal articles), market access, and publishing, all with advanced therapies experience. It also performs and/or supports the diligence process for investors or their targets as it knows what investors are looking for in an advanced therapy company, product, platform, tool, or related interest(s). The firm was intentionally built to be large enough to provide multi-disciplinary support across virtually every discipline required in advanced therapies, while remaining focused exclusively on that sector and relying on senior experts rather than junior execution teams.

The company's name also reflects how the business operates. "Hybrid Concepts" is not tied to hybrid work structures or remote office models, although HCI does work that way. Instead, the name reflects the firm's operating philosophy. HCI combines a client's therapeutic and/or platform concept(s) with HCI’s own scientific, regulatory and development expertise to create the strategies, submissions and development plans needed to move programs forward. HCI is also great at tactical task performance and management – it does all that is required -whether high-level or in the weeds, strategic or tedious. The resulting deliverables become a hybrid of the client's innovation and HCI's specialized expertise.

Sometimes that means supporting companies during early FDA interactions. In other situations, HCI is brought in after manufacturing issues, submission deficiencies or regulatory setbacks create challenges within a development program, where an efficient, effective, and “get the job done” approach is key.

The work changes depending on where the client sits in the process. The level of specialization does not.

Addressing the "Peaks and Valleys" Problem

Most advanced therapy companies face a resource challenge that extends beyond funding alone. For example, regulatory submissions, manufacturing activities and major FDA interactions create periods of intensive work followed by periods where the same expertise may be needed only intermittently. Maintaining large internal teams across every discipline can become difficult to justify when workloads fluctuate dramatically throughout development.

Dr. Mendicino describes it as the "peaks and valleys" problem.

A company preparing for a pre-IND interaction or IND submission may require months of intensive multi-disciplinary work involving manufacturing, quality, regulatory strategy, preclinical support and technical documentation. After those milestones, workloads often decline significantly before the next major phase of work tasks begins.

"A startup with one therapeutic program simply cannot logically hire dozens of full-time experts for intermittent activities," Dr. Mendicino says. "You need the right expertise during the peaks of work, but not necessarily during the valleys."

Some clients come into a consulting project with no internal regulatory or quality infrastructure at all. In those situations, the company can function almost as an outsourced multi-disciplinary development organization, handling everything from regulatory strategy and quality oversight to CMC planning, manufacturing support and submission publishing. Often times HCI fills in for one or more C-level roles as Acting or Interim.

Other organizations already have established internal teams and only require targeted expertise in specialized areas or during critical development stages. In those cases, HCI may lead specific projects, support existing teams or act as an expert “extra pair of eyes” review layer depending on the client's needs.

The company adjusts based on where support is actually required rather than forcing a fixed consulting structure onto every engagement. Also, HCI does not assign numerous project managers and admins that bill the client with little value add.

The flexibility has also helped HCI build long-term client relationships. Several clients have remained with HCI throughout much of the firm's decade-long history, utilizing HCI’s over 1000 years of collective advanced therapy subject matter expertise, progressing from early FDA interactions through later development milestones as programs advanced.

Over the last decade, HCI has supported approximately 190 clients worldwide across both therapeutic development programs and the technologies, platforms and service providers supporting the broader advanced therapies ecosystem. That is a significant slice of the overall advanced therapies market.

That operating model becomes particularly valuable in advanced therapies because development challenges rarely stop at staffing or resource allocation. The science itself often creates complex regulatory questions that require specialized expertise, particularly as agencies continue adapting oversight frameworks to emerging technologies.

Operating Inside Evolving Regulatory Environments

Advanced therapies often do not operate inside predictable development pathways.

Programs involving gene editing, engineered cell therapies or current clinical ready xenotransplantation often face evolving regulatory expectations as agencies continue adapting to newer technologies. In those situations, generalized consulting frameworks quickly become insufficient.

HCI stays closely connected to those changes through active participation and volunteer involvement in professional societies, industry organizations and working groups that regularly engage regulators on emerging advanced therapy issues. This involvement helps the company maintain visibility into evolving scientific, policy and regulatory developments affecting the sector.

The company also gains direct exposure through the breadth of programs it supports across preclinical, clinical and commercial development stages. While maintaining strict confidentiality between clients, HCI applies broader operational lessons and regulatory experience gained across programs to improve efficiency and strategic planning for future engagements.

That experience has led HCI to support some of the industry's most technically demanding advanced therapy programs.

In one engagement, HCI supported a viral gene therapy company after its Biologics License Application received a complete response from the FDA. HCI was brought in as a multi-disciplinary remediation partner, helping address issues involving quality, manufacturing, regulatory strategy and CMC/GMP compliance. The engagement represented a complete response remediation effort. Following corrective work involving quality, manufacturing, regulatory strategy and CMC documentation, the program ultimately progressed to marketing authorization.

Another engagement involved a non-U.S. company developing a highly complex allogeneic CAR-T therapy incorporating gene editing and other innovative technologies. Programs of that complexity frequently encounter FDA Holds during the IND process, particularly when companies are unfamiliar with the U.S. regulatory system. HCI supported the organization from early FDA interactions (INTERACT, and preIND) through successful IND submission. Despite the complexity of the product and development approach, the program advanced without being placed on clinical hold.

The company has also contributed to pioneering xenotransplantation work, including leading the multi-disciplinary regulatory efforts of one of the first FDA-allowed to proceed human clinical trials utilizing gene-modified pig organ xenotransplantation in the United States.

None of those are conventional biotech development programs.

Each involves complex science, evolving regulatory expectations and significant operational demands. That is precisely where HCI has positioned itself.

Building a More Global Support Structure

Although headquartered in the United States, the company increasingly operates through an international support structure.

HCI now has experts located across Canada, Europe, the UK, Australia and China to help clients navigate regional regulatory environments more effectively. American companies frequently seek support entering international development pathways, while organizations from Europe, Japan, China, India and Australia often require guidance navigating FDA processes in the United States. The model works in both directions, helping U.S. companies expand internationally while assisting overseas developers entering the U.S. regulatory environment. Having experts on the ground in those regions allows HCI to support development activity more effectively across jurisdictions.

At the same time, the company continues monitoring emerging technologies such as AI while maintaining a cautious approach toward their use in advanced therapies consulting.

"We ensure that human subject matter experts are significantly involved in generating, reviewing and compiling all of our work," Dr. Mendicino says.

For HCI, AI may support efficiency, but human expertise remains central to scientific, regulatory and development decision-making.

That philosophy reflects the broader culture of the organization itself.

HCI has not built its reputation through marketing and branding claims. Its reputation has been built through exclusive focus on advanced therapies, senior-led execution, one-stop-shop multi-disciplinary support and long-term involvement across some of the sector's most complex development programs.

The brand HCI has built and is proud of is culminated in its trademark slogan “Supporting the Development of Potential Cures”. That is what Dr. Mendicino has devoted his lifetime career toward, which is also the case for many of HCI’s experts.

As advanced therapies continue moving into more complex scientific and regulatory territory, companies increasingly need more than generalized consulting support. They need specialists already operating inside that complexity.

For its deep specialization, multi-disciplinary expertise and operational leadership across the advanced therapies landscape, Hybrid Concepts International has been recognized by Life Sciences Review as the Top Advanced Therapies Consulting and Advisory Firm 2026.